Brian H Kushner

8PUBLICATIONS
11CO-AUTHORS
Haematological tumoursNanotoxicology, health and safetyNanomedicineOncology and carcinogenesis not elsewhere classifiedEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

Brian H Kushner, Shakeel Modak, Charlie White

|Jan 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.

Brian H Kushner, Charlie White, Audrey Mauguen

|Nov 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.

Brian H Kushner, Shakeel Modak, Audrey Mauguen

|Jul 16, 2025
Rapid COJEC without myeloablative therapy for high-risk neuroblastoma.

Brian H Kushner, Ellen M Basu, Fiorella Iglesias Cardenas

|Jul 10, 2025
Clinical Significance of TERT Promoter Mutations in Neuroblastoma.

Natasha Persaud, Gunes Gundem, Brian H Kushner

|Mar 11, 2025
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission.

Brian H Kushner, Shakeel Modak, Audrey Mauguen

Pageof 2

Frequent Collaborators

6 joint publications

Shakeel Modak

2 joint publications

Stephen S Roberts

1 joint publications

Jessica Stiefel

1 joint publications

Fiorella Iglesias-Cardenas